ROCK1 is a potential combinatorial drug target for BRAF mutant melanoma
Abstract Treatment of BRAF mutant melanomas with specific BRAF inhibitors leads to tumor remission. However, most patients eventually relapse due to drug resistance. Therefore, we designed an integrated strategy using (phospho)proteomic and functional genomic platforms to identify drug targets whose...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer Nature
2014-12-01
|
| Series: | Molecular Systems Biology |
| Subjects: | |
| Online Access: | https://doi.org/10.15252/msb.20145450 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849331457126825984 |
|---|---|
| author | Marjon A Smit Gianluca Maddalo Kylie Greig Linsey M Raaijmakers Patricia A Possik Bas van Breukelen Salvatore Cappadona Albert JR Heck AF Maarten Altelaar Daniel S Peeper |
| author_facet | Marjon A Smit Gianluca Maddalo Kylie Greig Linsey M Raaijmakers Patricia A Possik Bas van Breukelen Salvatore Cappadona Albert JR Heck AF Maarten Altelaar Daniel S Peeper |
| author_sort | Marjon A Smit |
| collection | DOAJ |
| description | Abstract Treatment of BRAF mutant melanomas with specific BRAF inhibitors leads to tumor remission. However, most patients eventually relapse due to drug resistance. Therefore, we designed an integrated strategy using (phospho)proteomic and functional genomic platforms to identify drug targets whose inhibition sensitizes melanoma cells to BRAF inhibition. We found many proteins to be induced upon PLX4720 (BRAF inhibitor) treatment that are known to be involved in BRAF inhibitor resistance, including FOXD3 and ErbB3. Several proteins were down‐regulated, including Rnd3, a negative regulator of ROCK1 kinase. For our genomic approach, we performed two parallel shRNA screens using a kinome library to identify genes whose inhibition sensitizes to BRAF or ERK inhibitor treatment. By integrating our functional genomic and (phospho)proteomic data, we identified ROCK1 as a potential drug target for BRAF mutant melanoma. ROCK1 silencing increased melanoma cell elimination when combined with BRAF or ERK inhibitor treatment. Translating this to a preclinical setting, a ROCK inhibitor showed augmented melanoma cell death upon BRAF or ERK inhibition in vitro. These data merit exploration of ROCK1 as a target in combination with current BRAF mutant melanoma therapies. |
| format | Article |
| id | doaj-art-29adb95d2eb0448bb24189c0b9582da9 |
| institution | Kabale University |
| issn | 1744-4292 |
| language | English |
| publishDate | 2014-12-01 |
| publisher | Springer Nature |
| record_format | Article |
| series | Molecular Systems Biology |
| spelling | doaj-art-29adb95d2eb0448bb24189c0b9582da92025-08-20T03:46:34ZengSpringer NatureMolecular Systems Biology1744-42922014-12-01101211510.15252/msb.20145450ROCK1 is a potential combinatorial drug target for BRAF mutant melanomaMarjon A Smit0Gianluca Maddalo1Kylie Greig2Linsey M Raaijmakers3Patricia A Possik4Bas van Breukelen5Salvatore Cappadona6Albert JR Heck7AF Maarten Altelaar8Daniel S Peeper9Division of Molecular Oncology, The Netherlands Cancer InstituteBiomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Science, Utrecht UniversityDivision of Molecular Oncology, The Netherlands Cancer InstituteBiomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Science, Utrecht UniversityDivision of Molecular Oncology, The Netherlands Cancer InstituteBiomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Science, Utrecht UniversityBiomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Science, Utrecht UniversityBiomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Science, Utrecht UniversityBiomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Science, Utrecht UniversityDivision of Molecular Oncology, The Netherlands Cancer InstituteAbstract Treatment of BRAF mutant melanomas with specific BRAF inhibitors leads to tumor remission. However, most patients eventually relapse due to drug resistance. Therefore, we designed an integrated strategy using (phospho)proteomic and functional genomic platforms to identify drug targets whose inhibition sensitizes melanoma cells to BRAF inhibition. We found many proteins to be induced upon PLX4720 (BRAF inhibitor) treatment that are known to be involved in BRAF inhibitor resistance, including FOXD3 and ErbB3. Several proteins were down‐regulated, including Rnd3, a negative regulator of ROCK1 kinase. For our genomic approach, we performed two parallel shRNA screens using a kinome library to identify genes whose inhibition sensitizes to BRAF or ERK inhibitor treatment. By integrating our functional genomic and (phospho)proteomic data, we identified ROCK1 as a potential drug target for BRAF mutant melanoma. ROCK1 silencing increased melanoma cell elimination when combined with BRAF or ERK inhibitor treatment. Translating this to a preclinical setting, a ROCK inhibitor showed augmented melanoma cell death upon BRAF or ERK inhibition in vitro. These data merit exploration of ROCK1 as a target in combination with current BRAF mutant melanoma therapies.https://doi.org/10.15252/msb.20145450kinome shRNA genomic screeningPLX4720proteomicsROCK1 |
| spellingShingle | Marjon A Smit Gianluca Maddalo Kylie Greig Linsey M Raaijmakers Patricia A Possik Bas van Breukelen Salvatore Cappadona Albert JR Heck AF Maarten Altelaar Daniel S Peeper ROCK1 is a potential combinatorial drug target for BRAF mutant melanoma Molecular Systems Biology kinome shRNA genomic screening PLX4720 proteomics ROCK1 |
| title | ROCK1 is a potential combinatorial drug target for BRAF mutant melanoma |
| title_full | ROCK1 is a potential combinatorial drug target for BRAF mutant melanoma |
| title_fullStr | ROCK1 is a potential combinatorial drug target for BRAF mutant melanoma |
| title_full_unstemmed | ROCK1 is a potential combinatorial drug target for BRAF mutant melanoma |
| title_short | ROCK1 is a potential combinatorial drug target for BRAF mutant melanoma |
| title_sort | rock1 is a potential combinatorial drug target for braf mutant melanoma |
| topic | kinome shRNA genomic screening PLX4720 proteomics ROCK1 |
| url | https://doi.org/10.15252/msb.20145450 |
| work_keys_str_mv | AT marjonasmit rock1isapotentialcombinatorialdrugtargetforbrafmutantmelanoma AT gianlucamaddalo rock1isapotentialcombinatorialdrugtargetforbrafmutantmelanoma AT kyliegreig rock1isapotentialcombinatorialdrugtargetforbrafmutantmelanoma AT linseymraaijmakers rock1isapotentialcombinatorialdrugtargetforbrafmutantmelanoma AT patriciaapossik rock1isapotentialcombinatorialdrugtargetforbrafmutantmelanoma AT basvanbreukelen rock1isapotentialcombinatorialdrugtargetforbrafmutantmelanoma AT salvatorecappadona rock1isapotentialcombinatorialdrugtargetforbrafmutantmelanoma AT albertjrheck rock1isapotentialcombinatorialdrugtargetforbrafmutantmelanoma AT afmaartenaltelaar rock1isapotentialcombinatorialdrugtargetforbrafmutantmelanoma AT danielspeeper rock1isapotentialcombinatorialdrugtargetforbrafmutantmelanoma |